Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II Study to Assess the Efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients With Cystic Fibrosis.

Next Previous
Search
Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II Study to Assess the Efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients With Cystic Fibrosis.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2009

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 1236 (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Acronyms CYBER

Most Recent Events

  • 07 May 2009 Actual initiation date changed from 1 Jan 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
  • 07 May 2009 Planned end date changed from 1 Nov 2009 to 1 Aug 2010 as reported by ClinicalTrials.gov.
  • 02 May 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top